SELLAS Life Sciences Group (SLS) CFO granted 300,000 RSUs in Form 4
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
SELLAS Life Sciences Group, Inc. reported that its CFO, John Thomas Burns, received an award of 300,000 restricted stock units of common stock on January 7, 2026. The Form 4 shows this as an acquisition at a price of $0.00 per share, reflecting an equity compensation grant rather than an open‑market purchase.
The RSUs are scheduled to vest over four years: 25% on December 1, 2026 and 25% on each December 1 thereafter, as long as he remains in service with the company through each vesting date. After this grant, Burns is reported to beneficially own 554,327 shares of common stock, held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Burns John Thomas
Role
CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 300,000 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 554,327 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did SELLAS (SLS) report in this Form 4?
The company reported that CFO John Thomas Burns received an award of 300,000 restricted stock units of SELLAS common stock on January 7, 2026.
At what price were the SELLAS (SLS) RSUs granted to the CFO?
The Form 4 lists the acquisition of 300,000 shares of common stock at a price of $0.00 per share, indicating a compensatory RSU grant.
How do the 300,000 RSUs granted to the SELLAS CFO vest?
The 300,000 RSUs vest as follows: 25% on December 1, 2026 and 25% on each December 1 thereafter until fully vested, if he remains in service with SELLAS through each vesting date.
Is the SELLAS CFO considered a 10% owner in this Form 4?
No. The filing identifies John Thomas Burns as an officer (CFO) of SELLAS Life Sciences Group, Inc., and does not mark him as a 10% owner.